Company · Private
Immunis
Develops an immune-modulating secretome intended to counter age-related muscle and immune decline.
Listing
Private
Ticker
—
Headquarters
Irvine, US
Founded
2019
Technology
Immune secretome therapy
Category
Longevity thesis
Restoring immune signalling, not replacing cells, may be the cheaper route to functional benefit.
Programmes
- IMMUNAPhase 1/2
Muscle atrophy in older adults
Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.